Tensys® Medical Announces Completion of $20 + Million in Equity Funding

Significant Cash Infusion Reflective of Strong Traction in Non-Invasive Monitoring Market and Promise of "Breakthrough" Product Pipeline.

San Diego, CA | June 7, 2004 - Tensys® Medical, the leader in real-time, non-invasive blood pressure management, today announced the closing of $20 + million in equity funding. Leading the round was HBM BioVentures (Cayman) Ltd.. HBM BioVentures (Cayman) Ltd. is advised by HBM Partners AG, a global venture capital advisory group with over $800 million in managed assets. Additional significant participants in the round included the International Bank of Taiwan (IBT), and Medical Strategy Gmbh. Acting as an international advisor in the transaction, was Rockport Venture Securities, a wholly-owned subsidiary of Rockport Venture Partners.

The Tensys® T-Line® is an FDA cleared medical device providing anesthesiologists better, more effective control over patient safety during surgery by allowing them to quickly monitor and manage blood pressure variations.

"Throughout the due diligence process, we were most impressed by the strong support shown by the anesthesia community for Tensys, its management team and vision, as well as the T-Line® device itself," commented Dr. Beat Merz, Investment Advisor for medical devices with HBM Partners AG. "While the current T-Line® device is enjoying rapid and broad clinical adoption, it is the substantial product pipeline that has excited us most," continued Dr. Merz.

"HBM BioVentures (Cayman) Ltd., IBT and our additional European investors, are a welcomed and invaluable addition to the Tensys® team," commented Michael J. Martin, C.E.O. of Tensys® Medical, Inc. "Apart from raising this final round of financing, it was our strategic objective to gain a presence in both the European and Asian marketplace as we prepare our international distribution plans for the T-Line® system. With strong financial support and a wealth of both strategic and tactical experience now in place, Tensys® is well positioned to execute its global expansion strategy."

About Tensys® Medical

Tensys® Medical, Inc. is the leader in real-time blood pressure management. The Tensys T-Line, the company's lead product, was cleared by the FDA in November 2002 as a medical device providing anesthesiologists with a non-invasive, continuous real-time blood pressure management tool.

The Tensys® T-Line® measures a patient's blood pressure at the radial artery. It offers anesthesiologists better, more effective control over patient safety during surgery by allowing them to quickly monitor and manage blood pressure variations. The T-Line®, via its continuous, real-time data, is far more effective than the traditional cuff method and has clinically equivalent accuracy to that of the arterial line (A-line). The device is based on Tensymetry®, the company's proprietary and patented technology for non-invasively extracting the continuous, beat-to-beat pressure waveform from the radial artery without the use of any external calibration device. The science of Tensymetry® is broadly protected and is the result of over six years of research and development. Prior to its official product launch in March 2003, the Tensys® T-Line® was tested in approximately 500 surgical cases nationwide.

Tensys® Medical is based in San Diego, California and was founded in November 1995. For more information, please visit the company's Web site at www.tensysmedical.com.

Company Contacts:

Bill Markle
Vice President, Marketing & Business Development
Tensys® Medical, Inc.
858.522.1941 x211
bmarkle@tensysmedical.com

Media Contacts:

James Forte or Maureen O'Donnell
Townsend Inc.
858.457.4888
jforte@townsendinc.com
modonnell@townsendinc.com